Rotella Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Rotella Capital Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-2,240	Closed	-$1.04M	–	541
2015 Q3	$1.04M	Buy	+2,240	New	+$1.2M	0.34%	162
2014 Q4	–	Sell	-1,100	Closed	-$397K	–	426
2014 Q3	$397K	Buy	+1,100	New	+$369K	0.42%	48
2013 Q4	–	Sell	-800	Closed	-$250K	–	135
2013 Q3	$250K	Buy	+800	New	+$210K	0.47%	61

Other funds holding REGN

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Rotella Capital Management's REGN Position: Q4 2015 in Review

Rotella Capital Management sold out of Regeneron Pharmaceuticals (REGN) in Q4 2015, closing a stake of 2,240 shares — an estimated $1.04M sold.

Rotella Capital Management first reported a position in REGN in Q3 2013 and held it in 3 quarters. The position peaked at $1.04M in Q3 2015. 577 funds tracked by Wall St. Rank hold REGN as of Q4 2015.

Rotella Capital Management reported no remaining Regeneron Pharmaceuticals position as of Q4 2015 after selling out during the quarter.
Rotella Capital Management sold 2,240 Regeneron Pharmaceuticals shares in Q4 2015, an estimated $1.04M.
Rotella Capital Management first reported a position in Regeneron Pharmaceuticals in Q3 2013 and held it in 3 quarters.
Rotella Capital Management's Regeneron Pharmaceuticals position peaked at $1.04M in Q3 2015.
577 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2015.

Based on Rotella Capital Management's 13F filing for Q4 2015, filed 9 Feb 2016.